Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 8/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893889 | 0.90 | TRPA1 (0.40) | TRPA1PREPFAPDPP4ALDH1A1 | |
| SCHEMBL893953 | 0.86 | TRPA1 (0.52) | TRPA1KCNH2SCN5ASCN9AHDAC8 | |
| SCHEMBL13045904 | 0.85 | ALDH1A1 (0.51) | TRPA1GPR119SCN5AALDH1A1 | |
| SCHEMBL10201912 | 0.83 | ALDH1A1 (0.47) | HDAC8ALDH1A1 | |
| SCHEMBL893922 | 0.83 | ALDH1A1 (0.47) | HDAC8ALDH1A1 | |
| SCHEMBL3721342 | 0.82 | GPR119 (0.39) | TRPA1GPR119KCNH2SCN5ASCN9A | |
| SCHEMBL892976 | 0.79 | TRPA1 (0.68) | TRPA1 | |
| SCHEMBL893866 | 0.77 | TRPA1 (0.51) | TRPA1SCN9A | |
| SCHEMBL894009 | 0.76 | TRPA1 (0.42) | TRPA1PREPFAPHDAC8 | |
| SCHEMBL894253 | 0.75 | ALDH1A1 (0.53) | TRPA1SCN5AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | TRPA1 1/4885GPR119 622/4885KCNH2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.